Caris Life Sciences
246 hedge funds and large institutions have $2.75B invested in Caris Life Sciences in 2026 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 105 increasing their positions, 47 reducing their positions, and 24 closing their positions.
188% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 24
123% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 47
68% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $6.25M
22% more funds holding
Funds holding: 202 → 246 (+44)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
2% less capital invested
Capital invested by funds: $2.8B → $2.75B (-$53.2M)
1.02% less ownership
Funds ownership: 55.51% → 54.49% (-1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$55.5M |
| 2 |
MCO
MAK Capital One
New York
|
+$34.7M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
+$29.9M |
| 4 |
HF
HRT Financial
New York
|
+$25.4M |
| 5 |
Amundi
Paris,
France
|
+$21.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSP
Sixth Street Partners
Dallas,
Texas
|
-$126M |
| 2 |
JHWEPV
J. H. Whitney Equity Partners VI
New Canaan,
Connecticut
|
-$125M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$56.7M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$23.7M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$20.6M |
CAI Hedge Fund Activity: Q2 2026 in Review
246 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Caris Life Sciences (CAI) for Q2 2026, worth a combined $2.75B — down 1.9% from $2.8B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new CAI positions and 24 closed out — a net gain of 45 holders — while 105 added to existing stakes and 47 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $55.5M. The largest seller was Sixth Street Partners, cutting an estimated $126M.
- 246 institutional investors held Caris Life Sciences (CAI) as of Q2 2026, up from 202 in Q1 2026.
- Funds reported $2.75B of Caris Life Sciences stock for Q2 2026, down 1.9% quarter-over-quarter.
- 69 funds opened new Caris Life Sciences positions in Q2 2026 and 24 closed out, a net change of +45 holders.
- The largest Caris Life Sciences buyer in Q2 2026 was JP Morgan Chase, an estimated $55.5M added.
- The largest Caris Life Sciences seller in Q2 2026 was Sixth Street Partners, an estimated $126M sold.
Based on aggregated 13F filings for Q2 2026.